Coagulation

Copyright (c) 2005-2008, PathologyOutlines.com, Inc.

Reviewed by Kendall Crookston, MD, PhD (see reviewers page)

Last revised 10 June 2008

Last major update July 2005

Home Page

Printer Friendly Version

Bold and underlined topics are hypertext links within this document or to references

 

 

 

Table of Contents-Coagulation

 

Primary references, hemostasis-general, normal hemostasis, intrinsic pathway, extrinsic pathway, common pathway, protein C/S, thrombomodulin, antithrombin, fibrinolysis pathway, contact system

Bleeding disorders: general, laboratory approach                                                            

Acquired bleeding disorders: acute phase reaction, acquired dysfibrinogenemia, acquired von Willebrand’s disease, amyloidosis, bovine coagulation factor inhibitors, DIC, factor V inhibitor, factor VIII inhibitor, factor IX inhibitor, liver dysfunction, lupus anticoagulants, proteinuria, Vitamin K deficiency/warfarin

Hereditary bleeding disorders: general, algorithm for workup, factor I (fibrinogen) deficiency, factor II (prothrombin) deficiency, factor V deficiency, factor VII deficiency, factor VIII deficiency (hemophilia A), factor IX deficiency (hemophilia B), factor X deficiency, factor XI deficiency, factor XII deficiency, factor XIII deficiency, high molecular weight kininogen deficiency, prekallikrein deficiency, von Willebrand’s disease

Therapy related coagulopathies: warfarin, danaparoid, heparin, heparin-low molecular weight, hirudin, thrombolytic therapy

Acquired thrombophilia / hypercoagulopathies: general, antiphospholipid antibodies, heparin induced thrombocytopenia

Hereditary thrombophilia / hypercoagulopathies: general, activated protein C resistance / factor V Leiden, antithrombin deficiency, dysfibrinogenemia, elevated coagulation factors, heparin cofactor II deficiency, hyperhomocysteinemia, protein C deficiency, protein S deficiency, prothrombin gene mutation (G20210A), sickle cell disease

Coagulation laboratory tests: general, quality assurance, abnormal PT and PTT, activated clotting time, activated protein C resistance, anticardiolipin antibodies, antiplasmin, antithrombin, bleeding time, clot retraction, cryoglobulin / cryofibrinogen, D-dimer, ecarin clotting time, factor assays, factor I (fibrinogen) assay, factor V Leiden, factor VII assay, factor VIII assay, factor VIII inhibitor, factor IX assay, factor Xa assay, factor XI assay, factor XIII assay, heparin induced thrombocytopenia, heparinase, high molecular weight kininogen, homocysteine, hypercoagulation panel, INR, International sensitivity index, low molecular weight heparin, lupus anticoagulant, mixing studies, plasminogen assay, plasminogen activator antigen-1, platelet aggregation studies, platelet antibodies, platelet hyperaggregation studies, prekallikrein assay, protein C assays, protein S assays, prothrombin gene 20210A, PT, PTT, reptilase time, thrombin time, tPA, vWF testing-general, vWF antigen analysis, vWF activity, vWF multimer analysis

 

Primary references

top

 

Archives of Pathology and Laboratory Medicine (Archives), January 1976 to July 2005

Journal of Clinical Pathology, January 2001 to July 2005

Henry: Clinical Diagnosis and Management by Laboratory Methods, 2001 (20th edition)

Massachusetts General Hospital coagulation handbook

Journal search terms: coagulation

 

Please refer to these primary references for more detailed discussions and photographs

 

Hemostasis-general

top

Involves formation of blood clots to stop bleeding from damaged vessels, and activation of natural anticoagulation and fibrinolytic systems to limit clot formation to sites of injury

Bleeding disorders are due to defects in clot formation or overactive fibrinolytic systems

Hypercoagulability disorders are due to defects in anticoagulant system or underactive fibrinolytic systems

 

Normal hemostasis

top

Initial step is formation of platelet plug to stop bleeding from damaged vessel

Then, platelet plug is reinforced by fibrin clot

Then, fibrin clot is stabilized by activated factor XIII, which cross-links fibrin strands

Fibrin clot may occur via either intrinsic or extrinsic pathway (or both), though in vivo it occurs via a hybrid model

Coagulation factors in intrinsic or extrinsic pathway assemble on surface of activated platelets, which are usually at site of vascular injury

Many coagulation reactions also require calcium as a cofactor

Note: “a” after factor number indicates “activated”

Factor I: fibrinogen

Factor II: prothrombin

Factor III: tissue thromboplastin (tissue factor and phospholipid)

Factor IV: ionized calcium

Factor V: occasionally called labile factor or proaccelerin

Factor VI: unassigned

Factor VII: occasionally called stable factor or proconvertin

Factor VIII: antihemophilic factor

Factor IX: plasma thromboplastin component, Christmas factor

Factor X: occasionally called Stuart-Prower factor

Factor XI: occasionally called plasma thromboplastin antecedent

Factor XII: Hageman factor

Factor XIII: fibrin-stabilizing factor

Charts: coagulation cascade #1;  #2

 

Intrinsic pathway

top

Involves factors VIII, IX, XI, XII (Hageman factor), prekallikrein, high molecular weight kininogen

Merges with extrinsic pathway into common pathway

Activated when factor XII binds to negatively charged “foreign” surface exposed to blood

Then sequentially activates factors XI, IX, X, then factor II (prothrombin to thrombin), which converts fibrinogen to fibrin (see common pathway, below)

Once extrinsic pathway is inhibited by TFPI-Xa complex (see extrinsic pathway), factor VIIIa / IXa complex becomes dominant generator of factor Xa, thrombin and fibrin

Factor XIIa also converts prekallikrein to kallikrein, which activates more factor XIIa; both require high molecular weight kininogen as cofactors

Kallikrein also releases bradykinin from high molecular weight kininogen, which causes vasoconstriction

Charts: intrinsic pathway

 

Extrinsic pathway

top

Involves tissue factor (TF), originally considered “extrinsic” to blood since it is present on cell surfaces not normally in contact with (i.e. extrinsic to) the circulatory system

The primary mechanism of the coagulation pathway in vivo is tissue factor binding to activated factor VII (factor VIIa)

TF-Factor VIIa complex activates factors X and IX (though in vivo it appears to first involve factors VIII and V from the intrinsic pathway, which then activate factors X and IX)

Activated factor IX activates more factor X, with cofactors activated factor VIII, anionic phospholipids (from activated platelets) and calcium

Activated factor X converts prothrombin to thrombin, with activated factor V, anionic phospholipids (from activated platelets) and calcium as cofactors; prothrombin factor 1.2 is released (see common pathway, below)

After initial activation, pathway is inhibited by the binding of tissue factor pathway inhibitor (TFPI) to factor Xa, which inhibits TF-Factor VIIa complex, and further coagulation is dependent on the intrinsic pathway

Merges with extrinsic pathway into common pathway

Charts: coagulation cascade

 

Common pathway

top

Involves fibrinogen (factor I), factors II (prothrombin), V, X

Thrombin converts soluble fibrinogen to insoluble fibrin; releases fibrinopeptides A and B; remaining fibrin monomers polymerize to form fibrin; thrombin also binds to antithrombin, which inhibits thrombin to prevent excessive clotting

Thrombin may also activate factor XI (part of intrinsic pathway), factors V, VIII, XIII, XI and platelets

Factor XIII cross links fibrin to increase stability of fibrin clot

Charts: see normal hemostasis (above)

Diagrams: fibrinogen molecule

 

Protein C / Protein S anticoagulant pathway

top

Pathway is a physiologic anticoagulant system to limit blood clot formation (i.e. fibrinogen to fibrin conversion) to site of vessel injury

Major anticoagulant systems are protein C and protein S, antithrombin and tissue factor pathway inhibitor (TFPI, see Extrinsic pathway above)

Protein C and S: vitamin K dependent anticoagulant proteins produced mainly in liver (“C” because was third peak to elute from a diethylaminoethyl affinity column)

Activation: endothelial cell protein C receptor binds thrombin-thrombomodulin complex, which activates protein C, which binds to free protein S on endothelial or platelet phospholipids surfaces; this protein C / protein S complex degrades factors Va and VIIIa, which reduces fibrin formation

Activated protein C also indirectly promotes fibrinolysis

60-70% of protein S is bound to and inactivated by C4b binding protein, an acute phase reactant

Clinical note: since C4b increases during pregnancy, the protein S level will routinely fall below the normal non-pregnant range

Diagram: Protein C / Protein S anticoagulant pathway

References: Archives 2002;126:1337

 

Thrombomodulin

top

Intrinsic membrane glycoprotein on luminal surface of endothelial cells that binds thrombomodulin and facilitates the activation of protein C

C/T dimorphism at nucleotide 1418 is associated with premature myocardial infarction, but no definite association with venous thromboembolism

Drawings: thrombomodulin protein, flowchart of protein C activation

References: BMC Neurology 2004;4:21

 

Antithrombin

top

Formerly called antithrombin III

Functions as anticoagulant by inhibiting activated factors II (thrombin), IX, X, XI, XII, kallikrein, plasmin and probably factor VII (all are serine proteases)

Activity is accelerated 1000x by interaction with heparin or heparan sulfate (located on endothelial cells)

Member of serine protease inhibitor (serpin) gene family on #1q23-25

References: Archives 2002;126:1326

 

Fibrinolysis pathway

top

Process of degrading the fibrin clot when it is no longer needed

Also prevents extension of clot beyond site of injury

Initiated by tPA (tissue plasminogen activator) or uPA (urokinase-like plasminogen activator), which convert plasminogen to plasmin in the presence of fibrin by cleaving the Arg561-Val562 peptide bond

Plasmin degrades the fibrin clot and intact fibrinogen to soluble fibrin/fibrinogen degradation products (FDP)

Plasmin also inactivates factors Va and VIIIa (as does Protein C and Protein S)

tPA is produced by endothelial cells; its activation of plasminogen is major mechanism for lysis of fibrin clots

Recombinant tPA is used to treat myocardial infarction, stroke and some cases of acute thrombosis

uPA is produced by urine and plasma; keeps renal tracts free of blood clots; also is important for other cell surfaces and initiating nonfibrinolytic activities of plasmin

Excessive fibrinolysis is prevented by plasmin inhibitor (antiplasmin, formerly called alpha2-antiplasmin) and plasminogen activator inhibitor 1 (PAI-1, inhibits tPA and uPA)

PAI-1 is synthesized by hepatocytes and endothelial cells, is present in platelets and plasma; can bind to fibrin and inhibit plasminogen activators tPA and uPA

PAI-1 is an acute phase reactant protein, and may increase 30-50 fold over baseline, possibly immediately inactivating systemically administered tPA

Homozygous deficiency of plasminogen is associated with ligneous conjunctivitis (rare form of chronic pseudomembranous conjunctivitis), and replacement therapy with plasminogen is therapeutic

Neither heterozygous plasminogen deficiency (0.5 to 2.0% of patients with thrombosis) nor tPA deficiency are associated with increased risk of thrombosis

Diagrams: coagulation cascade and fibrinolytic system, diagram

References: Archives 2002;126:1376

 

Contact System

top

Consists of coagulation factors unknown in the 1950’s

Includes factor XII (Hageman factor), prekallikrein (PK; Fletcher factor), high molecular weight kininogen (Williams, Flaujeac or Fitzgerald factor); some authors include factor XI

Made in the liver

Decreased activity is associated with liver disease, hepatic immaturity in newborns, antiphospholipid syndrome, Asian descent (for factor XII)

Homozygous deficiencies are rare, autosomal recessive; cause very long PTT but no bleeding disorders and no definite association with hypercoagulability

Recommended to not measure their activity in routine evaluation of patients with arterial or venous thromboembolism or acute coronary syndromes (Archives 2002;126:1382)

Laboratory testing: homozygous deficiencies cause prolonged PTT; heterozygous deficiencies have near normal PTT; the test for a particular contact factor is based on the ability of the patient’s plasma to correct a prolonged PTT in plasma that is deficient in the factor being tested

Even though the PTT may be decreased by deficiencies of contact factors, this does not necessarily correlate with increased bleeding risk

 

 

Bleeding disorders

Bleeding disorders - general

top

Clinical history is important:

(a) single site (structural lesion) vs. multiple sites (coagulopathy)

(b) for coagulopathies - hereditary (family history of bleeding or bleeding since childhood) or acquired (no previous bleeding history)

(c) time from “hemostasis challenge” to bleeding symptoms - immediate suggests platelet disorder (inability to form normal platelet plug); late suggests coagulopathy (breakthrough bleeding occurs after platelet plug due to impaired fibrin formation)

(d) physical exam: petechiae (platelet disorders) vs. hematoma or hemarthrosis (coagulation defects) vs. mucous membrane bleeding or bruising (nonspecific)

 

Bleeding disorders are often classified as defects of primary hemostasis (platelets, vessels, etc.) or of secondary hemostasis (coagulation cascade and its regulation)

 

Bleeding disorders - laboratory approach

top

Laboratory tests should be ordered if (a) history or physical exam is suspicious for bleeding disorder or (b) for routine preoperative testing (PT, PTT, platelet count)

See algorithms for prolonged PT, prolonged PTT, abnormal platelet count (platelet chapter) or hereditary bleeding disorder (PT, PTT, and platelet count normal)

References: Crookston, K. P., and Spiess, B.D.; "Coagulation Support in the Perioperative Setting." in Simon: Rossi’s Principles of Transfusion Medicine; 2002 (3rd edition)

 

 

Acquired bleeding disorders

Acute phase reaction

top

Many serum proteins become elevated due to illness, injury, inflammation or stress; also pregnancy

Elevated levels return to normal after condition resolves

Causes increase in fibrinogen, factor VIII, vWF (up to 3x normal levels) and PAI-1 (up to 50x); decrease in PTT, decrease in protein S (due to binding to increased C4b)

 

Acquired dysfibrinogenemia

top

Usually caused by liver or biliary tract disease, acute phase reaction, hepatocellular carcinoma or renal cell carcinoma

Due to increased sialylation of fibrinogen’s carbohydrate side changes; this increases its net negative charge, which promotes charge repulsion between fibrin monomers and decreases the rate of fibrin polymerization

Tumor cells may secrete abnormal fibrinogen

Usually does not cause bleeding or thrombosis, but may in alcoholic liver disease

 

Acquired von Willebrand’s disease

top

Rare, either spontaneous or associated with hematologic neoplasms or autoimmune disorders

 

Amyloidosis

top

Primary amyloidosis may cause acquired factor X deficiency due to the binding of amyloid to factor X

Also inhibits fibrinogen conversion to fibrin, causing prolongation of thrombin time and reptilase time

 

Bovine coagulation factor inhibitors

top

After use of bovine “fibrin glue” to achieve hemostasis, 1.7% develop a clinically significant inhibitor

Some fibrin glue contains bovine thrombin and cryoprecipitate (containing human fibrinogen)

Antibodies may be formed against bovine thrombin, also against bovine factors V, VII, X (Archives 1998;122:887)

 

Disseminated intravascular coagulation (DIC)

top

Common, due to massive tissue injury, sepsis or other excessive activation of coagulation system; also pregnancy complications (abruptio placenta, amniotic fluid embolism, acute fatty liver of pregnancy, septic abortion), acute hemolytic transfusion reaction, snake bites, homozygous protein C deficiency, adult respiratory distress syndrome and hyaline membrane disease; chronic causes are cancer, liver disease, aortic aneurysm, retained dead fetus, giant hemangioma or head trauma

Anticoagulant and fibrinolytic systems are activated simultaneously and overwhelmed, leading to disseminated microthrombi and tissue ischemia, consumption of platelets, coagulation factors and natural anticoagulants, and variable bleeding

With malignancy, may get large vessel thrombosis

Activation of fibrinolytic system causes plasmin activation and formation of D-dimers and other fibrin degradation products

Schistocytes (fragmented red blood cells) are formed as red blood cells are severed flowing through fibrin strands

Laboratory: elevated D-dimers and other fibrin degradation products (FDPs), prolonged PT (70% of cases) and PTT (50%), decreasing platelets and fibrinogen (50%), schistocytes (50%); with chronic causes, fibrinogen and platelets may actually be elevated as acute phase reactants; all factors may be variably decreased due to factor activation and consumption

Baseline coagulation studies and serial followup are needed to follow the trends

Note: D-dimer may be falsely positive in HIV+ Castleman’s disease due to interference from monoclonal gammopathy (Archives 2004;128:328)

Treatment: treat underlying disease, transfuse fresh frozen plasma, platelets, cryoprecipitate if bleeding; keep fibrinogen levels above 100 mg/dL with cryoprecipitate or fresh frozen plasma; monitor PT, PTT, platelet count, fibrinogen and possibly antithrombin levels

Case reports: 30 year old woman with DIC due to amniotic fluid embolism (Archives 2002;126:869)

Micro images: schistocyte; amniotic fluid embolism - uterine wall -  figure 1: amniotic fluid debris; figure 2: lanugo hair

Diagrams: schematic of DIC

 

Factor V inhibitor

top

May behave like factor VIII inhibitor in mixing studies, with increasing PTT or PT after 1-2 hours

 

Factor VIII inhibitor

top

Most common clinically significant inhibitor; develops in 10-20% of patients with severe hemophilia A after infusion of factor VIII containing products, less often with mild/moderate disease

Rarely arises in patients without hereditary hemophilia, causing acquired hemophilia A (see below)

Causes prolonged PTT; in mixing study, PTT may initially be normal, then increases after 1-2 hours incubation

A nonlinear curve in a factor assay is often a clue to the presence of an inhibitor

Associated with normal PT

In patients with hemophilia A and factor VIII inhibitor, titer of inhibitor often increases after treatment with factor VIII containing products - this does not happen with autoimmune factor VIII inhibitor

Treatment with recombinant factor concentrates appears to lead to more inhibitors than plasma-derived concentrates

Each Bethesda unit of inhibitor indicates a decrease of factor VIII concentration in assay by 50% (1 unit: 100% to 50%; 2 units: 100% to 25%; 3 units: to 12.5%, etc.)

Treatment: porcine factor VIII (if no cross reactivity with inhibitor), prothrombin complex concentrates, FEIBA, recombinant factor VIIa (J Thromb Haemost 2004;2:899), immunosuppression for autoimmune based inhibitors

 

Nonhemophilic patients (autoimmune based inhibitors)

top

Incidence of 0.2 to 1 per million population per year

Causes bleeding

50% occur in patients with no known medical problems

Also associated with rheumatoid arthritis, SLE, post-partum; also solid tumors and hematologic malignancies

Laboratory: normal D-dimer and fibrinogen; prolonged PTT not corrected by mixing studies, nonlinear curve on assay for factor VIII

Treatment: recombinant factor VIIa, plasmapheresis (variable success), factor VIII, immunosuppression

References: Archives 2000;124:730

 

Factor IX inhibitor

top

Develops in 2-12% of patients with severe hemophilia B after transfusion of factor IX containing products, less commonly with mild/moderate disease

Rarely arises in patients without hereditary hemophilia, causing acquired hemophilia B

Causes a prolonged PTT, not corrected by mixing studies, and a nonlinear curve on the factor assay

Can quantitate titer of inhibitor

 

Liver dysfunction

top

Liver is site of production of most coagulation factors, but response of each factor to liver disease is variable due to differences in biologic half lives and acute phase reactions

PT usually prolonged first, then PTT

Factor VII: shortest biologic half life, often affected earliest with largest decrease in serum level

Clinical note: Factor VII also decreases earliest with warfarin treatment

Factor VIII: may be normal or elevated due to acute phase reaction

Factors XI and XII: long biologic half lives, may be normal until liver disease is advanced

 

Lupus anticoagulants

top

Common

Antibodies against protein-phospholipid complexes

Causes prolonged PTT (not time dependent), increased or normal PT; may interfere with assays for factors VIII, IX, XI and XII without causing a true decrease in factor levels

May be mistaken for a factor VIII inhibitor if dilutions to abnormal factor assays are not done

Not associated with bleeding, except when accompanied by severe thrombocytopenia or acquired factor II deficiency (rare)

May cause factor II deficiency if lupus anticoagulant binds to factor II

May be associated with thrombosis

Case reports: due to phenytoin use (Archives 1987;111:719)

 

Proteinuria

top

Patients with nephrotic syndrome may have decreased factors XI and XII

 

Vitamin K deficiency / warfarin use

top

Both have same molecular mechanism for their effects

Warfarin (coumadin): therapeutic anticoagulant to reduce risk of thromboembolism; impairs regeneration of active vitamin K

Vitamin K: cofactor in carboxylation of glutamic acid residues of factors II, VII, IX and X and protein S and C

Warfarin administration or Vitamin K deficiency cause prolonged PT; severe cases have prolonged PTT also

Vitamin K deficiency: due to fat malabsorption syndromes (vitamin K is a fat soluble vitamin), malnutrition, antibiotics (destroy bacteria producing vitamin K or interfere with vitamin K carboxylation), newborns

Treatment (warfarin overdose - INR > 5.0): fresh frozen plasma or vitamin K; PT should normalize within 12-24 hours

Clinical note: if a large dose of vitamin K is given, then it may be difficult to reach a therapeutic level of warfarin very quickly if the patient continues on warfarin therapy

Treatment (vitamin K deficiency): vitamin K once, then 12-24 hours later, then measure PT (should normalize)

 

 

Hereditary bleeding disorders

Hereditary bleeding disorders-general

top

Acquired factor deficiencies (due to liver disease, DIC, lupus anticoagulants, heparin, warfarin or other anticoagulants) are more common than hereditary factor deficiencies, and should be ruled out first

Heterozygous patients have 30-60% of normal values of affected factors, usually with no or minor bleeding disorder

However, factor I (hypofibrinogenemia or dysfibrinogenemia), X, XI or XIII deficient heterozygotes may have bleeding symptoms

Homozygous deficient patients have <30% of normal values of affected factors

In hemophilia A and B, small differences in factor levels (i.e. 1% vs. 3% vs. 10%) may markedly affect the clinical presentation and course

Hereditary disorders are confirmed by measuring factor levels in relatives

Combined factor deficiencies are very rare

Combined factor V and VIII: autosomal recessive, due to mutation in endoplasmic reticulum-Golgi gene ERGIC 53 on #18 that transports these factors

Combined factors II, VII, IX and X deficiency: due to mutation in gamma-glutamyl carboxylase gene, whose protein carboxylates glutamate residues in vitamin K-dependent coagulation factors

Very rare to have bleeding disorders due to deficiency in PAI-1 or antiplasmin

Symptoms: bleeding associated with surgery, trauma, dental extractions, postpartum, circumcision or umbilical stumps, GI bleeding, intracranial hemorrhage, hemarthrosis or soft tissue hematomas, easy bruising, epistaxis, menorrhagia

 

Algorithm for workup of hereditary bleeding disorders

top

Often there is a family history of bleeding disorder

PT, PTT, platelet count often normal

(a) Test for von Willebrand’s disease (most common hereditary bleeding disorder)

Testing for vWD includes Factor VIII activity, vWF antigen, vWF activity (often done by the “ristocetin cofactor” method); these results may lead to vWF multimer assays and blood type (type O patients have reduced vWF activity)

(b) Assays for fibrinogen, platelet aggregation or platelet function assay (e.g. PFA-100), factor XIII, dysfibrinogenemia (thrombin time or reptilase time)

(c) Also assays for factors VIII, IX or XI, even with normal PTT

(d) Factor XIII assay if delayed bleeding is present (often done by “urea clot lysis” method)

(e) More esoteric assays include PAI-1 activity and antiplasmin

 

Factor I / fibrinogen deficiency or disorders

top

Rare

Autosomal inheritance; most mutations are in alpha-fibrinogen chain gene, sparing beta and gamma chains

Often associated with bruising, epistaxis, menorrhagia, GI/GU bleeding, umbilical stump bleeding, miscarriage, poor wound healing; also bleeding after surgery, trauma, dental procedures, pregnancy or circumcision

May prolong PT and PTT

Need 100 mg/dL of fibrinogen for surgical hemostasis; biologic half life is 72-120 hours; less is needed in non-surgical conditions, if there is no severe hemostatic challenge

Afibrinogenemia: homozygous form; causes severe quantitative deficiency of fibrinogen and increased risk of bleeding; associated with intracranial hemorrhages

Hypofibrinogenemia: heterozygous form; mild/moderate reductions in fibrinogen; little/no bleeding

Dysfibrinogenemia: qualitative fibrinogen deficiency with production of dysfunctional fibrinogen; usually heterozygous; usually either no symptoms or mild bleeding; may paradoxically be associated with thrombosis, with or without bleeding; often prolonged thrombin time and reptilase time, PT and PTT

Acquired causes: DIC, liver dysfunction - more common than hereditary deficiencies

Treatment: 1 unit of cryoprecipitate per 7 kg as needed to keep fibrinogen above 100 mg/dL, if symptomatic; one unit raises fibrinogen by 10 mg/dL (approximately); one unit of fresh frozen plasma contains at least twice as much fibrinogen as one unit of cryoprecipitate, but in a much larger volume

 

Factor II (prothrombin) deficiency

top

Rare

Autosomal inheritance

Need 10-40% for surgical hemostasis; biologic half life is 48-120 hours

Severe deficiencies associated with intracranial hemorrhage

Acquired hypoprothrombinemia can be associated with lupus-like inhibitors

Treatment: recombinant factor VIIa, alternatively 10-20 ml fresh frozen plasma/kg, then 3 ml/kg every 12-24 hours as necessary; prothrombin complex concentrates may be used for serious bleeding

 

Factor V deficiency

top

Also called labile factor deficiency

Rare

Autosomal inheritance

Need 10-30% for surgical hemostasis, biologic half life is 12-36 hours

May be associated with bruising, epistaxis, menorrhagia, GI/GU bleeding, umbilical stump bleeding or bleeding after surgery, trauma, dental procedures, pregnancy or circumcision

Severe deficiencies associated with intracranial hemorrhage, although levels don’t always correlate with severity of symptoms

Treatment: 10-20 ml fresh frozen plasma/kg, then 3-6 ml/kg every 12 hours as necessary; commercial concentrates of factor V are not available

 

Factor VII deficiency

top

Also called autoprothrombin I deficiency

Rare

Autosomal inheritance

Need 10-25% for surgical hemostasis, biologic half life is 4-7 hours

May be associated with bruising, epistaxis, menorrhagia, GI/GU bleeding, umbilical stump bleeding or bleeding after surgery, trauma, dental procedures, pregnancy or circumcision

Severe deficiencies may resemble hemophilia A or B, and are associated with intracranial hemorrhage

Levels don’t always correlate with severity of symptoms

Treatment: 10-20 ml fresh frozen plasma/kg, then 3-6 ml/kg every 4 hours as necessary

 

Factor VIII deficiency (Hemophilia A)

top

Most common severe hereditary bleeding disorder

X linked recessive disorder; (gene is on X chromosome)

Need 80-100% for surgical hemostasis with major surgery or major bleeding, 30-50% postoperatively or to prevent minor bleeding

Biologic half life is 8-12 hours

Affects 1 per 5-10K males; female carriers are usually unaffected unless they have imbalanced inactivation (lyonization), Turner’s syndrome or other rare X chromosomal abnormalities; females with disease are rare (daughters of affected male and carrier female)

Clinical severity varies with factor levels: >5%: bleeding only with surgery or trauma; 1-5%; moderate bleeding; <1%: severe disease with spontaneous bleeding

30% of cases arise from new mutations, so there may be no family history

Symptoms: bleeding into muscle, soft tissue or joints (hemarthrosis), GI/GU tract; easy bruising, excessive bleeding after surgery, trauma, dental procedures or circumcision; epistaxis, poor wound healing, post-traumatic intracranial hemorrhage

Laboratory: prolonged PTT and normal PT in males with unexplained bleeding; measure factor VIII and IX levels (values of 20-30% of normal may cause prolonged PTT) and von Willebrand test panel (reduced factor VIII may be due to decrease in vWF; in female hemophilia A carriers, factor VIII/vWF ratio is 0.5 vs. 1.0 in normal females)

Notes: (a) factor VIII and vWF may be elevated during acute phase reactions, including pregnancy; must repeat tests when acute phase reaction has subsided; (b) factor VIII is labile at room temperature, and mild/moderate decreases may be due to improper processing and storage

Molecular: 40% in Caucasians are due to inversion of intron 22; also numerous other mutations; gene is large; RFLP analysis may be useful in families without the intron 22 mutation

Treatment: factor VIII concentrates (now treated to destroy viruses, but HIV+ in early 1980’s); 1 unit/kg raises levels in vivo by 2%

major surgery/bleeding - 40-50 units factor VIII concentrate/kg every 12 hours as necessary, usually for 7-10 days,

postoperatively - 15-25 units/kg every 12 hours as necessary, usually for 7-10 days

minor bleeding - 15-20 units/kg every 12-24 hours as necessary for minor bleeding

mild/moderate bleeding - DDAVP (if patients respond to DDAVP)

References: Mol Pathol 2002;55:127 (molecular aspects)

 

Factor IX deficiency (hemophilia B)

top

Also called Christmas disease, autoprothrombin II deficiency

Severe hereditary bleeding disorder

X lined recessive disorder (gene is on X chromosome)

Need 50-80% of normal levels for surgical hemostasis with major surgery or major bleeding, 40% postoperatively, 30-50% to prevent minor bleeding

Affects 1 per 25-30K males; female carriers are unaffected; females with disease are rare

Clinical severity varies with factor levels: >5%: bleeding only with surgery or trauma; 1-5%; moderate bleeding; <1%: severe disease with spontaneous bleeding

Factor half life is 18-24 hours

Symptoms: bleeding into muscle, soft tissue or joints (hemarthrosis), GI/GU tract; easy bruising, excessive bleeding after surgery, trauma, dental procedures or circumcision; epistaxis, poor wound healing, post-traumatic intracranial hemorrhage

Laboratory: prolonged PTT and normal PT in males with unexplained bleeding; measure factor VIII and IX levels (values of 20-30% of normal may cause prolonged PTT) and von Willebrand test panel

Molecular: numerous mutations; genetic testing for female carriers or prenatal detection uses RFLP analysis

Treatment: factor IX concentrates (now treated to destroy viruses, but HIV+ in early 1980’s); 1 unit/kg raises levels in vivo by 1%

major surgery/bleeding - 50-80 units factor IX concentrate/kg every 12-24 hours as necessary, usually for 7-10 days

postoperatively - 40 units/kg every 12-24 hours, usually for 7 days

minor bleeding - postoperatively; 30-40 units/kg q 12-24 hours as necessary

 

Factor X deficiency

top

Rare

Autosomal inheritance

Need 10-40% for surgical hemostasis, biologic half life is 24-48 hours

May be associated with bruising, epistaxis, menorrhagia, GI/GU bleeding, umbilical stump bleeding or bleeding after surgery, trauma, dental procedures, pregnancy or circumcision

Severe deficiencies may resemble hemophilia A or B, and are associated with intracranial hemorrhage

Treatment: 10-20 ml fresh frozen plasma/kg, then 3-6 ml/kg every 12 hours as necessary; may use prothrombin complex concentrates for serious bleeding

 

Factor XI deficiency

top

Common among Ashkenazi Jews

Autosomal inheritance

Need 15-50% for surgical hemostasis, biologic half life is 40-84 hours

May be associated with bruising, epistaxis, menorrhagia, GI/GU bleeding, umbilical stump bleeding or bleeding after surgery, trauma, dental procedures, pregnancy or circumcision

Levels don’t always correlate with severity of symptoms

Treatment: 10-20 ml fresh frozen plasma/kg, then 5-10 ml/kg every 24 hours as necessary

Note: factor XI concentrates may promote thromboembolic complications

 

Factor XII deficiency

top

Also called Hageman factor deficiency

Relatively common

Autosomal inheritance

Not needed in normal procoagulant pathways - deficiencies do not cause bleeding symptoms

May be implicated as cause of isolated, prolonged PTT after preanalytic variables and heparin contamination have been ruled out

Factor XII is activated by high molecular weight kininogen and prekallikrein

Activated factor XII converts prekallikrein to kallikrein, which activates more factor XII

 

Factor XIII deficiency

top

Rare

Autosomal inheritance

Need 5-50% for surgical hemostasis, biologic half life is 9-12 days

Although fibrin clots form, they are weak and subsequently lyse

Normal PT and PTT

Patients commonly present with history of delayed bleeding; often associated with bruising, epistaxis, menorrhagia, GI/GU bleeding, umbilical stump bleeding, miscarriage, intracranial hemorrhage, poor wound healing; also bleeding after surgery, trauma, dental procedures, pregnancy or circumcision

Testing recommended if delayed bleeding, umbilical stump bleeding, or miscarriages (with normal PT and PTT)

Diagnosis: usually with “urea clot lysis” assay, although specific factor assay is available in specialized labs

50% of population has Val134Leu polymorphism, which may protect against deep venous thrombosis, but predispose to intracranial hemorrhage

Acquired causes of factor XIII deficiency: liver disease, DIC, Crohn’s disease, ulcerative colitis, Henoch-Schonlein purpura, leukemia, myelodysplasia, myeloproliferative disorders

Treatment: 500 ml plasma or 1 bag cryoprecipitate / 10 kg every 3 weeks

 

High molecular weight kininogen deficiency

top

Rare

Autosomal inheritance

Not needed in normal procoagulant pathways - deficiencies may cause marked prolongation of PTT, but do not cause bleeding symptoms

 

Prekallikrein deficiency

top

Rare